Shield Therapeutics plc (LON:STX)
5.98p-2.76%
Spriggl Score: Moderate— see the number + sub-scores with a free Spriggl account
Last 30 trading days
Spriggl AI Verdict
“Growing 40% yearly with patent protection; Q1 earnings overstated and balance sheet remains under strain.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Shield Therapeutics plc
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the …
- Sector:
- Healthcare
- Industry:
- Drug Manufacturers - Specialty & Generic
- Market Cap:
- £63.3M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
Sign up for a free Spriggl account to unlock the full Spriggl Score breakdown, screener, watchlist, and AI investment analysis on Shield Therapeutics plc and 1,600+ UK and US stocks.
Start free